t
Hikma Pharmaceuticals PLC announced on 22 September 2026 that three Persons Discharging Managerial Responsibilities (PDMRs) acquired ordinary shares. On 21 September 2026, Susan Ringdal acquired 1,684 shares, Julie Hill acquired 218 shares, and Sam Park acquired 207 shares, all purchased via a dividend reinvestment plan at £15.97 per share on the London Stock Exchange.
| Date | 22 Sept 2026 |
| Time | 09:32:40 |
| Category | Director/PDMR dealings |
| ID | 7838V |
Hikma Pharmaceuticals PLC
(the "Company")
LONDON, 22 September 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibilities ("PDMRs") of the Company acquired Ordinary Shares in the Company, which were purchased under a dividend reinvestment plan ("DRIP").
This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Susan Ringdal |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Acquisition of Ordinary Shares through participation in a DRIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£15.97 |
1,684 |
||
|
d) |
Aggregated information |
Price(s): £15.97 Volume(s): 1,684 Total: £26,896.23 |
|
|
e) |
Date of the transaction |
21 September 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Julie Hill
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Julie Hill |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Acquisition of Ordinary Shares through participation in a DRIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£15.97 |
218 |
||
|
d) |
Aggregated information |
Price(s): £15.97 Volume(s): 218 Total: £3,481.82 |
|
|
e) |
Date of the transaction |
21 September 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Sam Park
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Sam Park |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
|
b) |
Nature of the transaction
|
Acquisition of Ordinary Shares through participation in a DRIP. |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£15.97 |
207 |
||
|
d) |
Aggregated information |
Price(s): £15.97 Volume(s): 207 Total: £3,306.13 |
|
|
e) |
Date of the transaction |
21 September 2026 |
|
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760